Retracted: Immunotherapy of metastatic breast cancer patients with vitamin D‐binding protein‐derived macrophage activating factor (GcMAF)

@article{Yamamoto2008RetractedIO,
  title={Retracted: Immunotherapy of metastatic breast cancer patients with vitamin D‐binding protein‐derived macrophage activating factor (GcMAF)},
  author={Nobuto Yamamoto and Hirofumi Suyama and Nobuyuki Yamamoto and Naofumi Ushijima},
  journal={International Journal of Cancer},
  year={2008},
  volume={122}
}
The above article from the International Journal of Cancer, published online on 12 October 2007 in Wiley Online Library and in Volume 122, Issue 2, pp 461–467, has been retracted by agreement between the journal Editor‐in‐Chief Peter Lichter and Wiley Periodicals, Inc. due to irregularities in the documentation for institutional review board approval. 

Retracted: Immunotherapy of HIV‐infected patients with Gc protein‐derived macrophage activating factor (GcMAF)

The above article, published online on 21 Nov 2008 Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between Dr. Ari Zuckerman and Wiley Periodicals, Inc. due to irregularities in the documentation for institutional review board approval.

The new aspects of immunotherapy in prostate cancer

Dear Editors, We read with a great interest your recently published paper on immunotherapeutic approaches to prostate cancer treatment [1]. Rigamonti and Bellone discussed interactions between the

Retraction Note to: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF

After 32–50 weekly administrations of 100 ng GcMAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells.

Role of vitamin D on cancer immunotherapy

It was confirmed that the level of vitamin D is related to Vitamin D binding proteins (Carpenter et al., 2012), and vitamin D has a prominent role in natural tumorocidal activity of immune system as an initial precursor.

Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells.

Results are consistent with the hypothesis that the known anticancer efficacy of DBP-MAF can be ascribed to different biological properties of the molecule that include inhibition of tumour-induced angiogenesis and direct inhibition of cancer cell proliferation, migration and metastatic potential.

Inconsistencies and questionable reliability of the publication “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF” by Yamamoto et al

It has been demonstrated that naturally occurring GcMAF in cancer patients has a concentration of approximately 4 mg/L, making the 100 ng proposed by Yamamoto meaningless and many references are used inappropriately and most do not support the authors’ claims.

Glycosylation status of vitamin D binding protein in cancer patients

The results suggest that alternative hypotheses regarding the molecular and/or structural origins of GcMAF must be considered to explain the relative inability of cancer patient serum to activate macrophages.

Epithelial Ovarian Cancer – Adjuvant Measures with Potential for Slowing Its Spread and Boosting or Restoring its Chemosensitivity

Adjuvant measures which could enhance or restore the responsiveness of EOC to chemotherapy drugs would be of great value and measures for slowing the growth and spread of E OC in the intervals between chemotherapy sessions would also be worthwhile.

Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.

After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had very low serum Nagalase levels equivalent to those of healthy control values, indicating that these patients are tumor-free.

CLINICAL EXPERIENCE OF CANCER IMMUNOTHERAPY INTEGRATED WITH OLEIC ACID COMPLEXED WITH DE-GLYCOSYLATED VITAMIN D BINDING PROTEIN

It is proposed that OA-GcMAF could demonstrate a greater immunotherapeutic activity than that of Gc MAF alone and combined with the known anticancer effects O a-protein complexes with the well-established immune stimulating effects of G cMAF.
...

References

SHOWING 1-10 OF 77 REFERENCES

Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1

It is concluded that for any report of augmented T‐cell responses against MUC1 to be convincing, one or more postimmunization blood samples will be needed to demonstrate augmented M UC1‐specific immunity consistently on multiple occasions.

Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.

A protracted macrophage activation induced by a few administrations of minute amounts of GcMAF eradicated the murine ascites tumor.

Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.

It is demonstrated that CA15-3 is more useful than CEA in monitoring the clinical course of patients with metastatic breast cancer and correlations obtained when using both antigens together failed to improve the results obtained with CA 15-3 alone.

Immunotherapy of Cancer: Regression of Tumors after Intralesional Injection of Living Mycobacterium bovis

Injection of living Mycobacterium bovis (strain BCG) into established intradermal tumors caused tumor regression and prevented the development of metastases.

Vitamin D and the Immune System

Considering the influence of vitamin D on the immune system, it may have potential as a treatment for immune-mediated diseases, even if additional research is required to better quantify dosage.

Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens

The complete absence of these antigens on cancers of neuroectodermal or mesodermal origin including melanoma, sarcoma, neuroblastoma and B cell lymphoma is as striking as their widespread presence on tumors of epithelial origin.

Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.

In Ehrlich ascites tumor-bearing mice, tumor-specific serum alpha-N-acetylgalactosaminidase (NaGalase) activity increased linearly with time as the transplanted tumor cells grew in the peritoneal cavity, and serum NaGalase activity was found to be highly correlated with survival time and total tumor cell count.

Structurally well‐defined macrophage activating factor derived from vitamin D3‐binding protein has a potent adjuvant activity for immunization

Although malignant tumours are poorly immunogenic, 4 days after GcMAF‐primed immunization of mice with heat‐killed Ehrlich ascite tumour cells, the ascites tumour was no longer transplantable in these mice.

Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides

Understanding the distribution of tumor‐associated antigens on cancers and normal tissues is essential for selection of targets for cancer immunotherapy. Seven carbohydrate antigens, potential

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.

  • M. SpielmannT. Dorval T. Tursz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1994
The encouraging response rates and duration achieved with this combination of Navelbine/doxorubicin in women who had received no prior chemotherapy for locally advanced or metastatic breast cancer deserve further randomized comparative trials with standard regimens.
...